Correction: Immunosuppressive FK506 treatment leads to more frequent EBV-associated lymphoproliferative disease in humanized mice

PLoS Pathogens

Home Correction: Immunosuppressive FK506 treatment leads to more frequent EBV-associated lymphoproliferative disease in humanized mice

Nicole Caduff, Donal McHugh, Anita Murer, Patrick Rämer, Ana Raykova, Vanessa Landtwing, Lisa Rieble, Christian W. Keller, Michael Prummer, Laurent Hoffmann, Janice K. P. Lam, Alan K. S. Chiang, Friedrich Raulf, Tarik Azzi, Christoph Berger,

... See all authors

https://doi.org/10.1371/journal.ppat.1009167, Volume: 16, Issue: 12, Pages: 1-1

Article Type: Correction Article History

Publisher: Public Library of Science

Altmetric

Table of Contents

Caduff,McHugh,Murer,Rämer,Raykova,Landtwing,Rieble,Keller,Prummer,Hoffmann,Lam,Chiang,Raulf,Azzi,Berger,Rubic-Schneider,Traggiai,Lünemann,Kammüller,and Münz: Correction: Immunosuppressive FK506 treatment leads to more frequent EBV-associated lymphoproliferative disease in humanized mice

The following information is missing from the Funding statement: AKSC was supported by a HMRF grant (18170462).

Reference

NCaduff, DMcHugh, AMurer, PRämer, ARaykova, VLandtwing, et al (2020) Immunosuppressive FK506 treatment leads to more frequent EBV-associated lymphoproliferative disease in humanized mice. PLoS Pathog 16(4): e1008477 10.1371/journal.ppat.1008477